Procoagulants/Blood Products Flashcards
What is the onset of Direct-Acting Non-Vit K Oral Anticoagulants?
Rapid onset of action; therapeutic anticoagulation occurs within hours of administration
What needs to be monitored with Direct-Acting Non-Vit K Oral Anticoagulants?
Don’t need routine monitoring
When is PCCs recommended?
- PCCs recommended for immediate INR reversal along w/vitamin-K administration
- PCCs also used for managing bleeding in patients receiving Xa inhibitors (apixaban, edoxaban, & rivaroxaban)
What can FFP be used for Management of Direct-Acting Non-Vit K Oral Anticoagulants?
- FFP can be used
- carries transfusion-related risk & risk of volume overload
What is the MOA of Platelet Inhibitors: Aspirin?
Irreversibly acetylates cyclooxygenase & prevents formation of thromboxane A2
How long do the effects of Platelet Inhibitors: Aspirin last?
Effects on platelets irreversible & last for life of the platelet: 7-10 days
Aspirin reduces incidence of ___________
occlusive arterial vascular events
Review cell membrane destruction.

What is the drugs in the class of Platelet Inhibitors: Thienopyridines?
clopidogrel (Plavix), prasugrel (Effient), & ticagrelor
What do Platelet Inhibitors: Thienopyridines (clopidogrel, prasugrel, & ticagrelor)?
These drugs irreversibly bind/antagonize platelet receptors which block adenosine diphosphate (ADP) binding which inhibits ADP-mediated platelet activation & aggregation
What are drugs involved in the Platelet Glycoprotein IIb/IIIa Antagonists?
abciximab (ReoPro), tirofiban (Aggrastat), eptifibatide (Integrilin)
What is the MOA of Platelet Glycoprotein IIb/IIIa Antagonists?
Drugs: abciximab (ReoPro), tirofiban (Aggrastat), eptifibatide (Integrilin)
- Block fibrinogen binding to platelet GP IIb/IIIa receptors that are a common pathway of platelet aggregation & inhibit platelet aggregation
What effect do Platelet Glycoprotein IIb/IIIa Antagonists have on platelet response?
Drugs: abciximab (ReoPro), tirofiban (Aggrastat), eptifibatide (Integrilin)
- Inhibit platelet function which inhibits platelet response to vascular injury & clot formation
- prevent thrombus formation initiated by platelets in acute coronary syndrome (unstable angina, myocardial infarction)
- angioplasty failure
- stent thrombosis
What is the Perioperative management of patients on platelet inhibitors?
(coming to the OR; having procedures requiring anesthesia) requires careful coordinated care between cardiology, surgeon, & anesthesia
What is the MOA of Thrombolytic Drugs?
These drugs act as plasminogen activators to convert endogenous plasminogen to plasmin which causes fibrinolysis (clot lysis)
What does Thrombolytic Drugs administration restore?
circulation through occluded artery or vein (usu coronary artery)
What is a risk with Thrombolytic Drugs?
Risk of bleeding (particularly intracranial hemorrhage) & hemorrhagic complications
What are Antifibrinolytic agents?
are procoagulants, promote hemostasis
What is the use for Antifibrinolytic Agents?
- used to treat bleeding perioperatively
- reduce need for transfusion (cardiac & orthopedic surgery, trauma)
What are examples of Antifibrinolytic Agents?
Synthetic lysine analog antifibrinolytic agents: aminocaproic acid (Amicar) & tranexamic acid (TXA)
What is the MOA of Antifibrinolytic Agents?
Antifibrinolytic Agents: Lysine Analogs
- These agents competitively inhibit activation of plasminogen to plasmin (enzyme that degrades fibrin clots) & fibrinogen
What can TXA cause?
TXA inhibits plasmin at high doses; risk of seizures
What is not a property of Antifibrinolytic Agents: Lysine Analogs?
- These agents are not prothrombotic
- they are clot stabilizers
- prevent compensatory responses of inflammatory injury & clot lysis
What does Antifibrinolytic Agents: Aprotinin?
Inhibits plasmin
